| Pregnancy data per womana . | 100 IU (n = 255) . | 150 IU (n = 266) . | RR [95% CI] . | P-value . |
|---|---|---|---|---|
| Ongoing pregnancy within 18 months of FU resulting in live birth | 169 (66.3%) | 185 (69.5%) | 0.953 [0.85–1.07] | 0.423 |
| First cycle | 91 (36.0%) | 104 (39.1%) | ||
| Second cycle | 39 (15.3%) | 45 (16.9%) | ||
| Third cycle | 24 (9.4%) | 18 (6.8%) | ||
| Fourth cycle | 4 (1.6%) | 6 (2.3%) | ||
| Fifth cycle | 0 | |||
| Biochemical pregnancy | 190 (74.5%) | 215 (80.8%) | 0.922 [0.84–1.01] | 0.083 |
| Clinical pregnancy | 180 (70.6%) | 207 (77.8%) | 0.907 [0.82–1.00] | 0.059 |
| Miscarriage | 18 (7.1%) | 32 (12.0%) | 0.587 [0.34–1.02] | 0.054 |
| Ongoing pregnancy | 173 (67.8%)e | 189 (71.1%)f | 0.955 [0.85–1.07] | 0.426 |
| Multiple pregnancyb | 5 (3.0%) | 12 (6.5%) | 0.434 [0.16–1.21] | 0.101 |
| Conception mode (% of live birth) | 0.748 | |||
| Spontaneous | 9 (5.3%) | 8 (4.3%) | ||
| IVF/ICSI freshc | 118 (69.8%) | 123 (66.8%) | ||
| IVF/ICSI cryo | 40 (23.7%) | 50 (27.2%) | ||
| Otherd | 2 (1.2%) | 4 (1.6%) | ||
| Time to ongoing pregnancy leading to live birth (days) | 185.4 (129.4) | 191.4 (129.8) | 0.664 |
| Pregnancy data per womana . | 100 IU (n = 255) . | 150 IU (n = 266) . | RR [95% CI] . | P-value . |
|---|---|---|---|---|
| Ongoing pregnancy within 18 months of FU resulting in live birth | 169 (66.3%) | 185 (69.5%) | 0.953 [0.85–1.07] | 0.423 |
| First cycle | 91 (36.0%) | 104 (39.1%) | ||
| Second cycle | 39 (15.3%) | 45 (16.9%) | ||
| Third cycle | 24 (9.4%) | 18 (6.8%) | ||
| Fourth cycle | 4 (1.6%) | 6 (2.3%) | ||
| Fifth cycle | 0 | |||
| Biochemical pregnancy | 190 (74.5%) | 215 (80.8%) | 0.922 [0.84–1.01] | 0.083 |
| Clinical pregnancy | 180 (70.6%) | 207 (77.8%) | 0.907 [0.82–1.00] | 0.059 |
| Miscarriage | 18 (7.1%) | 32 (12.0%) | 0.587 [0.34–1.02] | 0.054 |
| Ongoing pregnancy | 173 (67.8%)e | 189 (71.1%)f | 0.955 [0.85–1.07] | 0.426 |
| Multiple pregnancyb | 5 (3.0%) | 12 (6.5%) | 0.434 [0.16–1.21] | 0.101 |
| Conception mode (% of live birth) | 0.748 | |||
| Spontaneous | 9 (5.3%) | 8 (4.3%) | ||
| IVF/ICSI freshc | 118 (69.8%) | 123 (66.8%) | ||
| IVF/ICSI cryo | 40 (23.7%) | 50 (27.2%) | ||
| Otherd | 2 (1.2%) | 4 (1.6%) | ||
| Time to ongoing pregnancy leading to live birth (days) | 185.4 (129.4) | 191.4 (129.8) | 0.664 |
Data are presented ad mean (SD) or number (%) unless otherwise specified.
FU, follow-up, RR, relative risk. P-value calculated by using a Chi-square test.
aShown with a maximum of one event per woman.
bPercentage based on the number of multiple pregnancies.
cIncluding live births from escape IUI treatments.
dAfter treatment in another centre without cycle data.
e2 × Loss to FU, 1 × Foetal demise, 1 × Immature birth.
f2 × Foetal demise, 1 × Loss to FU, 1 × Termination of pregnancy for trisomy 21.
| Pregnancy data per womana . | 100 IU (n = 255) . | 150 IU (n = 266) . | RR [95% CI] . | P-value . |
|---|---|---|---|---|
| Ongoing pregnancy within 18 months of FU resulting in live birth | 169 (66.3%) | 185 (69.5%) | 0.953 [0.85–1.07] | 0.423 |
| First cycle | 91 (36.0%) | 104 (39.1%) | ||
| Second cycle | 39 (15.3%) | 45 (16.9%) | ||
| Third cycle | 24 (9.4%) | 18 (6.8%) | ||
| Fourth cycle | 4 (1.6%) | 6 (2.3%) | ||
| Fifth cycle | 0 | |||
| Biochemical pregnancy | 190 (74.5%) | 215 (80.8%) | 0.922 [0.84–1.01] | 0.083 |
| Clinical pregnancy | 180 (70.6%) | 207 (77.8%) | 0.907 [0.82–1.00] | 0.059 |
| Miscarriage | 18 (7.1%) | 32 (12.0%) | 0.587 [0.34–1.02] | 0.054 |
| Ongoing pregnancy | 173 (67.8%)e | 189 (71.1%)f | 0.955 [0.85–1.07] | 0.426 |
| Multiple pregnancyb | 5 (3.0%) | 12 (6.5%) | 0.434 [0.16–1.21] | 0.101 |
| Conception mode (% of live birth) | 0.748 | |||
| Spontaneous | 9 (5.3%) | 8 (4.3%) | ||
| IVF/ICSI freshc | 118 (69.8%) | 123 (66.8%) | ||
| IVF/ICSI cryo | 40 (23.7%) | 50 (27.2%) | ||
| Otherd | 2 (1.2%) | 4 (1.6%) | ||
| Time to ongoing pregnancy leading to live birth (days) | 185.4 (129.4) | 191.4 (129.8) | 0.664 |
| Pregnancy data per womana . | 100 IU (n = 255) . | 150 IU (n = 266) . | RR [95% CI] . | P-value . |
|---|---|---|---|---|
| Ongoing pregnancy within 18 months of FU resulting in live birth | 169 (66.3%) | 185 (69.5%) | 0.953 [0.85–1.07] | 0.423 |
| First cycle | 91 (36.0%) | 104 (39.1%) | ||
| Second cycle | 39 (15.3%) | 45 (16.9%) | ||
| Third cycle | 24 (9.4%) | 18 (6.8%) | ||
| Fourth cycle | 4 (1.6%) | 6 (2.3%) | ||
| Fifth cycle | 0 | |||
| Biochemical pregnancy | 190 (74.5%) | 215 (80.8%) | 0.922 [0.84–1.01] | 0.083 |
| Clinical pregnancy | 180 (70.6%) | 207 (77.8%) | 0.907 [0.82–1.00] | 0.059 |
| Miscarriage | 18 (7.1%) | 32 (12.0%) | 0.587 [0.34–1.02] | 0.054 |
| Ongoing pregnancy | 173 (67.8%)e | 189 (71.1%)f | 0.955 [0.85–1.07] | 0.426 |
| Multiple pregnancyb | 5 (3.0%) | 12 (6.5%) | 0.434 [0.16–1.21] | 0.101 |
| Conception mode (% of live birth) | 0.748 | |||
| Spontaneous | 9 (5.3%) | 8 (4.3%) | ||
| IVF/ICSI freshc | 118 (69.8%) | 123 (66.8%) | ||
| IVF/ICSI cryo | 40 (23.7%) | 50 (27.2%) | ||
| Otherd | 2 (1.2%) | 4 (1.6%) | ||
| Time to ongoing pregnancy leading to live birth (days) | 185.4 (129.4) | 191.4 (129.8) | 0.664 |
Data are presented ad mean (SD) or number (%) unless otherwise specified.
FU, follow-up, RR, relative risk. P-value calculated by using a Chi-square test.
aShown with a maximum of one event per woman.
bPercentage based on the number of multiple pregnancies.
cIncluding live births from escape IUI treatments.
dAfter treatment in another centre without cycle data.
e2 × Loss to FU, 1 × Foetal demise, 1 × Immature birth.
f2 × Foetal demise, 1 × Loss to FU, 1 × Termination of pregnancy for trisomy 21.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
